Tanriverdi, Elif SerenBayindir, YasarYakupogullari, YusufToplu, Sibel AltunisikKarabulut, ErtugrulDuman, YucelOtlu, Baris2026-04-042026-04-0420260732-88931879-0070https://doi.org/10.1016/j.diagmicrobio.2025.117077https://hdl.handle.net/11616/109655Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infection is a major cause of mortality in liver transplantation (LT) recipients. Methods: We aimed to elucidate the molecular mechanisms of carbapenem resistance among CRKP strains and determine ceftazidime-avibactam (CZA) in vitro susceptibility in high-risk patient populations, such as LT recipients. Results: Of the 127 LT recipients between January 2016 and 2022, no statistically significant difference was found in the in vitro sensitivity of amikacin, gentamicin, ciprofloxacin, levofloxacin, imipenem, meropenem, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, tigecycline, and colistin in patients with CRKP sepsis who survived and died at 30 days, except for amikacin and meropenem, which was statistically significant at 90 days (p <= 0.05). Of the isolates, 120 (94.4 %) were positive for the modified carbapenem inactivation test. When the carbapenemase genes of 127 CRKP isolates were analyzed, the most common carbapenemase gene was OXA-48 (59.1 %). The presence of OXA-48, OXA-48 + NDM, NDM, IMP, and VIM genes in CRKP isolates showed a statistically significant difference with the CZA susceptibility result (p < 0.05). Conclusions: The presence of the OXA-48 resistance gene in CRKP isolates was closely associated with in vitro susceptibility to CZA, regardless of the diversity of the patient population.eninfo:eu-repo/semantics/closedAccessCarbapenem-resistant Klebsiella pneumoniaeLiver transplantationLiving donorCeftazidime-avibactamCarbapenemase genesArticle11414085429210.1016/j.diagmicrobio.2025.1170772-s2.0-105013841004Q2WOS:001561393200001Q30000-0002-5545-34670000-0002-0449-03560000-0002-5433-591X